These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24258145)

  • 41. Balancing innovation, access, and profits--market exclusivity for biologics.
    Engelberg AB; Kesselheim AS; Avorn J
    N Engl J Med; 2009 Nov; 361(20):1917-9. PubMed ID: 19828525
    [No Abstract]   [Full Text] [Related]  

  • 42. Biosimilars--science, status, and strategic perspective.
    Kresse GB
    Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 44. The year's new drugs & biologics, 2011.
    Graul AI; Cruces E; Dulsat C; Arias E; Stringer M
    Drugs Today (Barc); 2012 Jan; 48(1):33-77. PubMed ID: 22384459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strategic balance of drug lifecycle management options differs between domestic and foreign companies in Japan.
    Yamanaka T; Kano S
    Expert Opin Ther Pat; 2016; 26(4):497-503. PubMed ID: 26881292
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Fewer new drugs from drug industry].
    Reikvam A
    Tidsskr Nor Laegeforen; 2007 Nov; 127(23):3106-7. PubMed ID: 18049505
    [No Abstract]   [Full Text] [Related]  

  • 47. Fresh from the biologic pipeline-2009.
    Sheridan C
    Nat Biotechnol; 2010 Apr; 28(4):307-10. PubMed ID: 20379168
    [No Abstract]   [Full Text] [Related]  

  • 48. Who needs faster drug approval times in Canada: the public or the industry?
    Lexchin J
    Int J Health Serv; 1994; 24(2):253-64. PubMed ID: 8034392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Companies line up for hereditary angioedema market.
    Huggett B
    Nat Biotechnol; 2008 Apr; 26(4):364-5. PubMed ID: 18392002
    [No Abstract]   [Full Text] [Related]  

  • 51. Cancer research fund launches biologics pilot plant.
    Subbaraman N
    Nat Biotechnol; 2010 Oct; 28(10):995-6. PubMed ID: 20944573
    [No Abstract]   [Full Text] [Related]  

  • 52. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009: comments on the article by M Neovius et al.
    Ohlsson H; Merlo J
    Scand J Rheumatol; 2011 May; 40(3):243-4. PubMed ID: 21529245
    [No Abstract]   [Full Text] [Related]  

  • 53. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The year's new drugs & biologics - 2008.
    Graul AI; Revel L; Barrionuevo M; Cruces E; Rosa E; Verges C; Lupone B; Diaz N; Castaner R
    Drug News Perspect; 2009; 22(1):7-29. PubMed ID: 19209296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 57. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1.
    Kuhrt K; Chace-Ortiz M
    IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implementation of Plate Imaging for Demonstration of Monoclonality in Biologics Manufacturing Development.
    Zingaro K; Shaw D; Carson J; Mayer-Bartschmid A; Bender C; Alves C; Mcvey D; Qian NX; Wei Q; Laird MW; Zhu Y; Emmins R; Follit JA; Porter A; Racher AJ; Milne S; Carubelli I; Du Z; Khatri A; Failly M; Broly H; Lee F; Reeser M; Spidel J; Anderson K; Demaria C; Di-Carlo J; Gill J; Lundquist A; Kumar SR; Gill T
    PDA J Pharm Sci Technol; 2018; 72(4):438-450. PubMed ID: 29669815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Biosimilars or follow-on biologics in dermatology].
    Puig L
    Actas Dermosifiliogr; 2010; 101(1):4-6. PubMed ID: 20109387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.